Lipoprotein apheresis for the treatment of elevated circulating levels of lipoprotein(a): a critical literature review

被引：17
|
作者：
Franchini, Massimo [1 ]
Capuzzo, Enrico [1 ]
Liumbruno, Giancarlo M. [2 ]
机构：
[1] Carlo Poma Hosp, Dept Haematol & Transfus Med, Mantua, Italy
[2] Italian Natl Blood Ctr, Natl Inst Hlth, Rome, Italy
来源：
BLOOD TRANSFUSION | 2016年 / 14卷 / 05期
关键词：
lipoprotein apheresis; lipoprotein(a); thrombosis; TRANSFER PROTEIN INHIBITOR; CORONARY-HEART-DISEASE; CARDIOVASCULAR-DISEASE; FAMILIAL HYPERCHOLESTEROLEMIA; LIPID APHERESIS; DOUBLE-BLIND; RISK-FACTOR; LDL-C; SAFETY; EFFICACY;
D O I：
10.2450/2015.0163-15
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Lipoprotein(a), which consists of a low-density lipoprotein (LDL) particle linked to an apolipoprotein(a) moiety, is currently considered an independent risk factor for cardiovascular disease due to its atherogenic (LDL-like) and prothrombotic (plasminogen-like) properties. The aim of this review is to provide an overview of the current and newer therapies for lowering increased lipoprotein(a) levels, focusing on lipoprotein apheresis. After a systematic literature search, we identified ten studies which, overall, documented that lipoprotein apheresis is effective in reducing increased lipoprotein(a) levels and cardiovascular events.
引用
收藏
页码：413 / 418
页数：6
相关论文
共 50 条
  • [21] Long-term lipoprotein apheresis in the treatment of severe familial hypercholesterolemia refractory to high intensity statin therapy: Three year experience at a lipoprotein apheresis center
    Mickiewicz, Agnieszka
    Borowiec-Wolna, Justyna
    Bachorski, Witold
    Gilis-Malinowska, Natasza
    Galaska, Rafal
    Raczak, Grzegorz
    Chmara, Magdalena
    Wasag, Bartosz
    Jaguszewski, Milosz J.
    Fijalkowski, Marcin
    Gruchala, Marcin
    CARDIOLOGY JOURNAL, 2019, 26 (06) : 669 - 679
  • [22] Influence of lipoprotein apheresis on circulating plasma levels of miRNAs in patients with high Lp(a)
    Dlouha, Dana
    Prochazkova, Iveta
    Eretova, Zuzana
    Hubacek, Jaroslav A.
    Parikova, Alena
    Pitha, Jan
    ATHEROSCLEROSIS SUPPLEMENTS, 2019, 40 : 12 - 16
  • [23] Real-world study: Escalating targeted lipid-lowering treatment with PCSK9-inhibitors and lipoprotein apheresis
    Spitthoever, Ralf
    Roeseler, Tilmann
    Julius, Ulrich
    Heigl, Franz
    Schettler, Volker J. J.
    Kuehn, Ralf
    Leebmann, Josef
    Raabe, Andrea
    Knittel, Markus
    Schuerfeld, Carsten
    Moesenthin, Michael
    Bernhardt, Wanja M.
    Roeseler, Eberhard
    Ketteler, Markus
    Heibges, Andreas
    Klingel, Reinhard
    JOURNAL OF CLINICAL APHERESIS, 2019, 34 (04) : 423 - 433
  • [24] Lipoprotein-apheresis: Austrian consensus on indication and performance of treatment
    Kurt Derfler
    Sabine Steiner
    Helmut Sinzinger
    Wiener klinische Wochenschrift, 2015, 127 : 655 - 663
  • [25] Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levels
    Schettler V.J.J.
    Neumann C.L.
    Peter C.
    Zimmermann T.
    Julius U.
    Hohenstein B.
    Roeseler E.
    Heigl F.
    Grützmacher P.
    Blume H.
    Klingel R.
    Vogt A.
    Clinical Research in Cardiology Supplements, 2019, 14 (Suppl 1) : 33 - 38
  • [26] Pharmacotherapy for children with elevated levels of lipoprotein(a): future directions
    de Boer, Lotte M.
    Wiegman, Albert
    Swerdlow, Daniel, I
    Kastelein, John J. P.
    Hutten, Barbara A.
    EXPERT OPINION ON PHARMACOTHERAPY, 2022, 23 (14) : 1601 - 1615
  • [27] Lipoprotein(a)-hyperlipoproteinemia as cause of chronic spinal cord ischemia resulting in progressive myelopathy – successful treatment with lipoprotein apheresis
    Heigl F.
    Hettich R.
    Mauch E.
    Klingel R.
    Fassbender C.
    Clinical Research in Cardiology Supplements, 2017, 12 (Suppl 1) : 50 - 54
  • [28] Elevated circulating levels of lipoprotein-associated phospholipase A2 in obese children
    Sakka, Sophia
    Siahanidou, Tania
    Voyatzis, Chronis
    Pervanidou, Panagiota
    Kaminioti, Christina
    Lazopoulou, Natalia
    Kanaka-Gantenbein, Christina
    Chrousos, George P.
    Papassotiriou, Ioannis
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2015, 53 (07) : 1119 - 1125
  • [29] Reduced Oxidative Susceptibility of Lp(a) and LDL Fractions as a Pleiotropic Effect of Lipoprotein Apheresis in Patients with Elevated Lp(a) and ASCVDs
    Krzesinska, Aleksandra
    Marlega-Linert, Joanna
    Chyla-Danil, Gabriela
    Marcinkowska, Marta
    Rogowska, Paulina
    Stumska, Katarzyna
    Fijalkowski, Marcin
    Gruchala, Marcin
    Jankowski, Maciej
    Mickiewicz, Agnieszka
    Kuchta, Agnieszka
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (24)
  • [30] ELEVATED LEVELS OF LIPOPROTEIN (A) IN CHILDREN WITH FAMILIAL HYPERCHOLESTEROLEMIA
    WIDHALM, K
    GENSER, D
    WIENER KLINISCHE WOCHENSCHRIFT, 1994, 106 (07) : 197 - 200
12345